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SUMMARY
Background
Non-alcoholic fatty liver disease generally has a benign course; however,
patients with non-alcoholic steatohepatitis (NASH) may progress to cirrho-
sis and hepatocellular carcinoma. Currently, there is a lack of consensus
about optimal NASH treatment.
Aim
To assess the efficacy of insulin-sensitizing agents on histological and bio-
chemical outcomes in randomized control trials of biopsy-proven NASH.
Methods
Multiple online databases and conference abstracts were searched. Random
effects meta-analyses were performed, with assessment for heterogeneity
and publication bias.
Results
Nine trials were included; five trials using thiazolidinediones (glitazones),
three using metformin and one trial using both drugs. There was no publi-
cation bias. Compared with controls, glitazones resulted in improved steato-
sis (WMD = 0.57, 95% CI 0.36–0.77, P = <0.001), hepatocyte ballooning
(WMD = 0.36, 95% CI 0.24–0.49, P < 0.001) and ALT (WMD = 16.4, 95%
CI 7.7–25.0, P < 0.001), but not inflammation (P = 0.09) or fibrosis
(P = 0.11). In patients without diabetes, glitazones significantly improved
all histological and biochemical outcomes, most importantly including
fibrosis (WMD = 0.29, 95% CI 0.078–0.51, P = 0.008). Metformin failed to
improve any pooled outcome.
Conclusions
Treatment of NASH with glitazones, but not metformin, demonstrates a
significant histological and biochemical benefit, especially in patients with-
out diabetes. Additional studies are needed to investigate long-term out-
comes of glitazone therapy in patients without diabetes.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a growing
health concern in the United States. It is the most com-
mon cause of liver disease, afflicting up to 30–40% of the
general population and 60–91% of patients with underly-
ing diabetes or morbid obesity.1–4 NAFLD has been
shown to be an independent risk factor for increased
cardiovascular morbidity and mortality.5–8 Whereas the
majority of patients with NAFLD have simple steatosis
that has a benign course, about 20% of patients will have
a more severe form known as non-alcoholic steatohepatis
(NASH), a histological diagnosis that consists of steato-
sis, hepatocyte ballooning and lobular inflammation with
or without fibrosis. Compared with patients with simple
steatosis, those with NASH are more likely to progress to
cirrhosis, liver failure, or hepatocellular carcinoma.9
However, there are currently no established treatments
for NASH other than lifestyle modification and weight
loss, which are often difficult to achieve and even harder
to maintain.10–12
A predominant feature of NAFLD is insulin resistance,
the central mechanism in the development of hepatic
steatosis. Insulin resistance leads to altered adipokine pro-
duction and increased outflow of free fatty acids, resulting
in hepatocellular accumulation of toxic lipid-derived
metabolites and activation of multiple inflammatory path-
ways.13–15 Over time, this process can lead to activation
of fibrogenic hepatic stellate cells.16 Therefore, several
studies have explored the ability of insulin sensitizers to
improve biochemical and histological features of fibrosis
and inflammation in NAFLD. The two main groups of
insulin-sensitizing drugs that have been evaluated for
NASH treatment are thiazolidinediones and metformin.
Thiazolidinediones (also known as the ‘glitazones’) are
high-affinity ligands of peroxisome proliferator-activated
receptor-c (PPAR-c), that stimulate the storage of free
fatty acids in subcutaneous adipocytes as opposed to liver
and omental fat, thereby improving insulin sensitivity.17
Metformin is an insulin-sensitizer that acts by decreasing
hepatic glucose production and increasing skeletal muscle
glucose uptake.
Conclusions about the role of insulin-sensitizing
agents such as thiazolidinediones (glitazones) or metfor-
min for the treatment of NASH from currently available
studies are limited due to small sample size, hetero-
geneous study endpoints and a range of methodological
quality. The purpose of this meta-analysis is to summa-
rize the currently available evidence for the efficacy of




A computer-assisted search was conducted to identify
potentially relevant publications in the OVID MEDLINE
database on 27 January 2010. The search (1997 to January
2010) was performed using the following exploded
(exp) medical subject heading (MeSH), textwords, and
truncated text words ($): metformin, thiazolidinedione
(exp), pioglitazone, rosiglitazone, insulin sensitiz$, thera-
peutics (exp), treatment, fatty liver (exp), non-alcoholic
fatty liver disease, non-alcoholic steatohepatitis, steatosis,
NAFLD, NASH, liver. The preceding terms were com-
bined with appropriate Boolean logic, and this search was
then limited to humans and adults. A similar search was
also performed in EMBASE, Pubmed and the Cochrane
Central Register of Controlled Trials from 1997 to 2010.
Additional electronic searches of Digestive Diseases
Week (DDW) abstracts, American Association for Study
Liver Diseases of (AASLD) meeting abstracts, American
College of Gastroenterology (ACG) meeting abstracts and
European Association for the Study of the Liver (EASL)
meeting abstracts for the period from 2005 to 2009 were
performed with combinations of the search terms ‘fatty
liver’ or ‘steatohepatitis’ or ‘NASH’ and ‘treatment’. A
manual search of abstracts from these years was also per-
formed. Manual recursive searches of references from
review articles and published randomized controlled trials
that met inclusion criteria were also completed. Finally,
consultation with expert hepatologists was performed to
identify any additional abstracts or unpublished data.
Study selection criteria
Potentially relevant studies were selected based on the
following inclusion criteria: (i) randomized controlled tri-
als using an insulin sensitizer drug that is currently
FDA-approved (metformin, rosiglitazone, pioglitazone);
(ii) diagnosis of NASH determined by histology; (iii)
liver biopsy performed at beginning and end of clinical
trial; and (iv) adult patients. Studies in which NASH was
diagnosed based on elevated transaminases or abnormal
imaging studies (ultrasound, CT scan, magnetic reso-
nance imaging) without histological confirmation were
excluded. Studies that involved weight loss therapies such
as orlistat or bariatric surgery were not included because
they primarily target weight loss and only secondarily
affect insulin resistance.18
All randomized controlled trials, regardless of publica-
tion status, number of patients randomized, language, or
blinding were included. Studies published only as abstracts
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were included if they had sufficient information on study
design, characteristics of participants, interventions and
outcomes and ⁄ or if an author of the abstract could pro-
vide this information. One investigator (MR) reviewed the
titles and abstracts of all citations identified by the litera-
ture search. Potentially relevant studies were retrieved.
Two investigators (MR, AS) independently applied the
selection criteria, and any disagreements were resolved by
consensus. Agreement between investigators for selection
of studies for the meta-analysis was greater than 95%.
Data extraction
Eligible articles were reviewed in a duplicate, indepen-
dent manner by two investigators (MR, AS). For each
study, the investigators collected the following data: (i)
Study: year, location, design, publication status; (ii)
Treatment: dose, frequency, duration, active diet and
exercise education throughout trial; (iii) Patients: num-
ber, mean age, gender, presence of diabetes; (iv) Anthro-
pometrics and laboratory tests (baseline and end of
study): BMI, ALT; and (v) Histology (baseline and end
of study): steatosis grade, hepatocyte ballooning score,
lobular inflammation score and fibrosis stage. If data
were not available in the published article, the investiga-
tors contacted the corresponding authors for additional
information. Any discrepancies in data quantification
were resolved by discussion among the investigators.
Primary and secondary outcomes
The primary outcomes for this meta-analysis were histo-
logical responses to treatment, specifically changes in: (i)
steatosis grade (0–3), (ii) hepatocyte ballooning score (0–
2), (iii) lobular inflammation score (0–3), or (iv) fibrosis
stage (0–4). The secondary outcomes included (i) bio-
chemical response, measured as change in ALT and (ii)
anthropometric response, measured as change in body
mass index (BMI).
Quality assessment
Study quality was assessed using the Cochrane Collabo-
ration’s tool for assessing risk of bias.19 As opposed to
other assessment tools that utilize scales or check lists,
this tool utilizes domain-based evaluation, which focuses
on criteria that are more highly associated with internal
validity in RCTs. Quality assessment was based on the
following domains: (i) randomization, (ii) allocation con-
cealment, (iii) blinding of participants, personnel, and
outcome assessors, (iv) completeness of outcome data,
(v) unbiased outcome reporting and (vi) lack of other
sources of bias. Studies were categorized as high quality
if all six domains were well described and low quality if
one or more domains were not well described.
Statistical analysis
The outcomes were calculated as mean difference in
scores in the intervention group and were compared with
the mean difference in scores in the control group, as
described by the following equation: (treatment mean
at baseline – treatment mean at the end of the study) –
(control mean at baseline – control mean at the end
of the study). Therefore, if the histological response to
treatment improved to a greater extent in the treatment
compared with the control group, the weighted mean
difference (WMD) would be positive. Likewise, if the
response improved to a greater extent in the control
group compared with the treatment group, the WMD
would be negative. Difference in means for each outcome
for intervention and control group was either directly
obtained from the study results or calculated by deter-
mining the difference between reported mean values
before and after treatment. However, studies did not
report the s.d. of the change in means, but reported only
the s.d. of the preintervention mean and the s.d. of the
postintervention mean. One study provided the s.d. of the
change in means for all outcomes upon request.25 For
those studies that reported a P-value for the comparison
between pre- and postintervention mean values,26–28, 33 a
s.d. for the change in means was derived through back-
calculation. For those studies without P-values, t-statistics,
or confidence intervals,30–32 we imputed the s.d. of the
change in means, using a modified method by Follmann
et al.: s.d.change in means = sq root [(s.d.pre)
2 + (s.d.post)
2 )
(2(q) · s.d.pre · s.d.post)].20 This equation estimates the
s.d. of the change in means (s.d.change in means) using the
s.d. of preintervention mean (s.d.pre) and the s.d. of post-
intervention mean (s.d.post) as well the within-participant
correlation (q) of the outcome measure. We initially
assumed a within-participant correlation of zero to derive
the largest standard deviation of the change in means,
which thereby calculates the most conservative measure-
ment of pooled s.d. for this meta-analysis. A subsequent
sensitivity analysis was performed using varied measure-
ments of q (q = 0.4, q = 0.8) to evaluate if varied levels
of within-participant correlation altered the statistical
significance for each outcome.
Estimates of effect, WMD, were pooled using the
DerSimonian and Laird method for a random effects
model. For each outcome variable, a forest plot was
created that illustrates both study-specific and pooled
WMD with 95% confidence intervals. Heterogeneity was
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assessed using the Cochrane Q statistic and the inconsis-
tency index (I2).21, 22 A chi-square P-value <0.05 or I2
>50% is consistent with the possibility of substantial
heterogeneity.22 Influence analysis, in which one study is
removed at a time from the model, was performed to
determine if there was a possible undue influence of a
single study.23 Publication bias was graphically examined
using a symmetric funnel plot, and then statistically
using the test of Egger.24 A contour-enhanced symmetric
funnel plot helps to rule out bias due to small studies
that were not published due to unfavourable results. All
statistics were computed using STATA 11.0 (StataCorp LP,
College Station, TX, USA).
Subset analysis was performed for predefined subsets
of studies based on (i) type of insulin sensitizer, (ii)
exclusion of patients with diabetes, (iii) use of concurrent
diet and exercise, (iv) inclusion of patients with benign
steatosis in addition to patients with NASH, (v) length
of follow-up and (vi) study quality.
RESULTS
Literature search
A total of 185 citations were retrieved using our search
strategy, and all citations were downloaded into EndNote.
Search of abstracts from the annual meetings of Ameri-
can Association for Study of Liver Diseases (AASLD),
American College of Gastroenterology (ACG), European
Association for the Study of the Liver (EASL) and Diges-
tive Disease Week (DDW) for the period from 2005–
2009 yielded 12 potentially relevant abstracts. Recursive
searches of article references identified three additional
articles. After review of the titles and abstracts of all of
these articles (n = 200), 181 were excluded. Nineteen
studies underwent full text review to determine their eli-
gibility. Of these, two were initially in abstract form. A
full manuscript was provided by one author after being
contacted for more information. The other abstract was
published soon after abstract presentation and therefore
full manuscript was included in this meta-analysis. After
review of the 19 full text articles, a total of nine studies
were included in this meta-analysis (Figure 1,
Table 1).25–33 Although important as the original study
that investigated the use of insulin sensitizers for the
management of NAFLD, we excluded Caldwell’s impor-
tant trial involving troglitazone because this trial was not
a randomized controlled trial and therefore did not meet
our inclusion criteria.34 There did not appear to be any
publication bias by Egger’s test (P = 0.73) or funnel plot
analysis (data not shown).







by recursive review 
n = 3
Articles retrieved for 
full text review
n = 19
Excluded (n = 181) 
- Not NAFLD/NASH: 85 
- Not insulin Sensitizer: 74 
- Not RCT: 4 
- No bx for NAFLD/NASH
      diagnosis: 3
- No end of study bx: 4 
- Previously published
  cohort: 7 
- Review article: 3 




1End of study biopsy was available for the control, but not for the treatment group
n = 200
Excluded (n = 10) 
- No bx for NAFLD/NASH
      diagnosis: 7
- No end of study biopsy1: 1
- Not RCT: 2 
Figure 1 | Map of the literature
search and selection process.
RCT, randomized controlled
study; bx, biopsy.
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Study description
Of the nine trials included in our meta-analysis, six
investigated the use of glitazones.25–30 These studies used
either pioglitazone or rosiglitazone, with a treatment
duration of 96 weeks,25 48 weeks,26, 27, 29, 30 or
24 weeks.28 All six trials excluded patients with benign
steatosis and enrolled only patients with NASH. Of note,
Idilman et al. had three arms (rosiglitazone, metformin,
control); therefore, this study was included in subgroup
analysis for both glitazones and metformin.30
Four trials investigated the use of metformin30–33 using
dosages ranging from 500 mg31 to 3000 mg33 daily. Dura-
tion of treatment was 24 weeks in two studies32, 33 and
48 weeks in the other two.30, 31 All trials enrolled only
patients with NASH except one which also included
patients with simple steatosis.33 One trial32 did not report
results of histological outcomes other than fibrosis and
therefore only three trials30, 31, 33 were included for analysis
of steatosis, hepatocyte ballooning and lobular inflammation.
Outcomes
Primary outcome: histological response. Table 2 summa-
rizes the pooled treatment effect WMD (weighted mean
difference) of insulin sensitizers for all analyses. Analysing
all nine studies together, insulin sensitizing agents resulted
in a significant improvement in fibrosis (P = 0.011) and
steatosis (P = 0.003) compared with controls, but not
ballooning (P = 0.10) or inflammation (P = 0.29).
In subgroup analysis, glitazones resulted in a signifi-
cant reduction in steatosis (P < 0.001) and hepatocyte
ballooning (P < 0.001) compared with controls (Table 2,
Figure 2). Glitazones did not result in improvement in
lobular inflammation (P = 0.09) or fibrosis (P = 0.11)
compared with the control group. Metformin did not
improve pooled treatment effects for any of the histologi-
cal outcomes (Table 2); specifically, there was no associ-
ated improvement in fibrosis (P = 0.51).
Secondary outcomes: biochemical and anthropometric
response. When analysing all included studies, insulin
sensitizing agents did result in improvement in ALT
(P = 0.014) compared with controls (Table 2). Glitazones
resulted in a highly significant decrease in ALT com-
pared with controls (P < 0.001), whereas metformin did
not improve pooled treatment effects for biochemical
outcome (P = 0.10).
Overall, BMI improved (i.e. decreased from baseline)
to a greater extent in the control group than in the
group receiving insulin sensitizers (WMD = )1.23;
P < 0.001). In particular, BMI improved in the controls
compared with the patients receiving glitazones only
(P = 0.010), whereas metformin use did not result in sig-
nificant change in BMI compared with the control group
(P = 0.39) (Table 2).
Sensitivity analyses
As described previously, variance imputation was initially
performed using a within-participant correlation of zero
(q = 0.0). Sensitivity analysis using other values of q
(q = 0.4, q = 0.8) revealed no difference in trends for
each outcome, yielding similar findings for all statistical
analyses (data not shown).
Table 2 | Summary of effect sizes (weighted mean difference) for all insulin sensitizers, glitazones and metformin com-
pared with controls
Outcomes
All insulin sensitizers Glitazones Metformin
WMD* 95% CI P-value WMD* 95% CI P-value WMD* 95% CI P-value
Primary outcome: histological response
Steatosis 0.40 0.14, 0.65 0.003 0.57 0.36, 0.77 <0.001 )0.19 )0.69, 0.31 0.45
Ballooning 0.16 )0.031, 0.35 0.10 0.36 0.24, 0.49 <0.001 )0.037 )0.19, 0.12 0.64
Inflammation 0.17 )0.15, 0.48 0.29 0.29 )0.05, 0.63 0.09 )0.19 )0.55, 0.17 0.31
Fibrosis 0.24 0.053, 0.42 0.011 0.21 )0.046, 0.46 0.11 0.22 )0.37, 0.81 0.46
Secondary outcome: biochemical and anthropometric response
ALT 11.9 2.4, 21.5 0.004 16.4 7.70, 25.0 <0.001 13.6 )2.7, 29.9 0.10
BMI )1.23 )1.61, )0.85 <0.001 )0.90 )1.59, )0.22 0.010 0.75 )0.97, 2.48 0.39
WMD, weighted mean difference; CI, confidence interval; DM, diabetes mellitus; ALT, alanine aminotransferase; BMI, body mass
index.
* WMD: a positive WMD indicates greater improvement in the treatment group compared with controls.
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An additional sensitivity analysis was performed to
assess any effect of study quality. Four of the nine trials
were considered low quality,26, 30–32 primarily due to
inadequate descriptions of allocation concealment or
blinding, whereas the others were considered high qual-
ity25, 27–29, 33 (Table S1). At the time of baseline and end
of study biopsies, pathologists in all studies were blinded
to randomization. Intention-to-treat analysis was used in
all but two trials.27, 30
Other preplanned subset analyses failed to affect sig-
nificantly any of our primary or secondary outcomes.
There was only one study33 that enrolled patients with
simple steatosis; in addition, those with NASH and
removal of this study did not affect overall outcomes.
Active diet and ⁄ or exercise education during the clinical
trial27, 28, 30, 31 did not affect outcomes, nor did study
duration.
Sensitivity analyses for glitazone trials. Given the large I2
for one of the primary outcomes in the glitazone trials
(inflammation, I2 = 73.8%), additional sensitivity analyses
were performed for the glitazone subset. The first assessed
undue influence from the PIVENS trial, the largest RCT
for NASH treatment to date. Exclusion of the PIVENS
data did not change the primary outcomes of our meta-
analysis (Table 3). Specifically, after excluding the PIVENS
trial from analysis, glitazones continued to demonstrate a
significant improvement in steatosis (P = 0.01) and
ballooning (P < 0.001) compared with controls, but not
inflammation (P = 0.39) and fibrosis (P = 0.33) (Table 3).
An additional sensitivity analysis was performed to
assess any change in pooled outcomes related to study
quality. When including only high quality studies,25, 27–29
significance of primary and secondary outcomes
remained the same, except that a significant decrease in
inflammation was found (WMD = 0.37; 95% CI 0.04–
0.70; P = 0.03) (Table 3).
The final glitazone sensitivity analysis assessed trials
that specifically excluded patients with diabetes.25–27 All
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WMD (95% CI) Weight (%)
0.57 (0.36, 0.77)  100.00
0.82 (0.07, 1.57)  7.20
0.40 (–0.18, 0.98)  12.34
0.30 (–0.85, 1.45)  3.10
0.21 (–0.39, 0.81)  11.45
0.72 (0.44, 1.00)   53.50
0.31 (–0.26, 0.88)  12.40
Favors control Favors glitazones Favors control Favors glitazones
Favors control Favors controlFavors glitazones Favors glitazones
Figure 2 | Forest plots demonstrating pooled effect of glitazones on histological outcomes: a. steatosis, b. hepatocyte
ballooning, c. inflammation and d. fibrosis.
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Table 3 | Sensitivity analyses for glitazones
Outcomes
Excluding PIVENS25 High quality studies only25, 27–29 Non-DM trials only25–27
WMD* 95% CI P-value I2 WMD* 95% CI P-value I2 WMD* 95% CI P-value I2
Primary outcome: histological response
Steatosis 0.39 0.09, 0.68 0.01 0 0.57 0.30, 0.84 <0.001 18 0.59 0.34, 0.84 <0.001 8
Ballooning 0.39 0.25, 0.52 <0.001 0 0.32 0.11, 0.53 0.002 16 0.37 0.14, 0.59 0.001 0
Inflammation 0.21 )0.27, 0.68 0.39 78 0.37 0.04, 0.70 0.03 75 0.35 0.071, 0.64 0.014 46
Fibrosis 0.18 )0.18, 0.54 0.33 46 0.22 )0.04, 0.49 0.10 25 0.29 0.078, 0.51 0.008 0
Secondary outcome: biochemical and anthropometric response
ALT 12.0 )0.70, 24.7 0.06 27 20.7 19.2, 22.1 <0.001 0 19.2 5.11, 33.2 0.008 47
BMI )0.59 )1.27, 0.09 0.09 14 )1.39 )1.48, )1.30 <0.001 0 )1.23 )1.9, )0.57 <0.001 14
WMD, weighted mean difference; CI, confidence interval; I2, inconsistency index; DM, diabetes mellitus; ALT, alanine aminotrans-
ferase; BMI, body mass index.
* WMD: a positive WMD indicates greater improvement in the treatment group compared with controls.

































































Favors control Favors glitazones Favors control Favors glitazones
Favors control Favors glitazones Favors control Favors glitazones
Figure 3 | Forest plots demonstrating pooled effects of glitazones on histological outcomes in trials that excluded
patients with diabetes: (a) steatosis, (b) hepatocyte ballooning, (c) inflammation and (d) fibrosis.
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a minimum duration of 48 weeks. When patients with
diabetes were excluded, pioglitazone resulted in a signifi-
cant decrease in all histological and biochemical out-
comes, including fibrosis (WMD = 0.29; 95% CI 0.078–
0.51; P = 0.008) (Figure 3, Table 3). In addition, there
was a significant increase in BMI (P < 0.001).
DISCUSSION
To date, conclusions about the efficacy and safety of
insulin sensitizers for the treatment of NASH have been
difficult due to the small sample size and heterogeneity
of available trials. Our study is the largest and most
comprehensive meta-analysis of randomized controlled
trials evaluating the role of glitazones and metformin in
these patients. We found that glitazones significantly
improved steatosis, hepatocyte ballooning and serum
ALT levels compared with controls, but not lobular
inflammation or fibrosis. However, in patients without
diabetes, glitazones resulted in significant decreases in all
histological outcomes, including fibrosis. In contrast,
metformin was found to be an ineffective treatment for
NASH as it was not superior to controls for any histo-
logical or biochemical outcome.
Given that glitazones have potential serious side
effects35 and will probably need to be taken long-
term,36, 37 it is important to determine which subset of
patients, if any, would most benefit from prolonged glit-
azone therapy. This meta-analysis offers novel insights
into tailoring NASH therapy and suggests that glitazone
treatment should be focused on patients who have not
yet developed diabetes. Pooled data from trials that
enrolled only patients without diabetes25–27 demonstrated
a significant decrease in all biochemical and histological
outcomes, including fibrosis (P = 0.008), the endpoint
ultimately thought to be the most important in NASH
treatment in preventing disease progression. Further-
more, Ratziu et al. found that absence of diabetes was an
independent predictor of histological response in NASH
patients treated with rosiglitazone (OR=0.14, 95% CI
0.02–0.79, P = 0.026).29 Together, these findings suggest
that patients without overt diabetes may be particularly
susceptible to the insulin sensitizing properties of glitaz-
ones and that early intervention may prevent worsening
of insulin resistance, as well as its downstream complica-
tions such as NASH progression.
There are several potential mechanisms to explain the
differential benefit of glitazones on inflammation and
fibrosis in patients with and without diabetes. First, glit-
azones may prevent the development of insulin resis-
tance by preservation of pancreatic beta cell function and
by increasing the effectiveness of endogenous insulin, as
seen in studies of high-risk populations such as patients
with impaired glucose tolerance (IGT), impaired fasting
glucose (IFG), or a history of gestational diabetes.38–40
Specifically, the DREAM trial, a large, multicentre trial
that randomized 5269 patients with IFG or IGT to
receive rosiglitazone or placebo for a median of 3 years
found that rosiglitazone reduced the risk of developing
diabetes or death by 60% compared with placebo, with
an absolute risk difference of 14.4%.38 Our findings sug-
gest that glitazones may arrest NASH progression, per-
haps through a similar mechanism of delayed or halted
development of insulin resistance and ⁄ or preventing
worsening of insulin resistance in those who do not
already have overt diabetes. Second, any improvement in
fibrosis from glitazone use is probably indirect and medi-
ated through anti-inflammatory pathways given that
PPAR-gamma is minimally expressed in activated hepa-
tic stellate cells.41 Therefore, in diabetics, the potent anti-
inflammatory effects of glitazones42 may be surpassed by
the pro-inflammatory state associated with insulin resis-
tance state and diabetes,43 thereby potentially making
this class of drugs less effective for NASH treatment
among patients with diabetes.
In the recently published PIVENS trial,25 pioglitazone
failed to meet the composite primary endpoint, which
required a decrease in NAFLD Activity Score (NAS)44 of
at least two points with at least one point decrease in
ballooning and no worsening of fibrosis (P = 0.04;
P < 0.025 considered significant due to three-arm
design). This trial was a three-arm randomized con-
trolled trial comparing 96 weeks of pioglitazone, vitamin
E, and placebo for treatment of nondiabetic patients with
NASH. However, when each histological component that
comprises the NAS was assessed individually, pioglitaz-
one did result in a significant decrease in steatosis, hepa-
tocyte ballooning and lobular inflammation compared
with controls (P < 0.001, 0.01 and <0.001 respectively).
A trend towards greater mean decrease in fibrosis (week
96 fibrosis stage -baseline fibrosis stage) was found for
pioglitazone compared with controls ()0.36  0.96 and
0.13  0.89 respectively); however, it did not reach sta-
tistical significance (P = 0.10). Amongst the trials that
enrolled only nondiabetic patients including the PIVENS
study,25–27 our meta-analysis found a significant decrease
in fibrosis with glitazone therapy compared with controls
in patients without diabetes (P = 0.008) with minimal
heterogeneity between trials for this outcome (I2 = 0%).
Although the PIVENS trial is the largest randomized
controlled trial to date, change in fibrosis was only a
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secondary endpoint and therefore it is likely that the trial
may have been underpowered to detect a difference of
this magnitude. Our meta-analysis suggests that glitazone
therapy may improve fibrosis for select populations such
as those without diabetes.
This meta-analysis has a few limitations that warrant
discussion. First, selection and referral bias should be con-
sidered given that all of the included trials were conducted
in tertiary care centres. Second, our method for weighting
studies made assumptions that resulted in the largest vari-
ance for the pooled effect size. Therefore, it is possible that
95% confidence intervals for the WMD are wider and
more conservative than what would be expected if the
within-person correlations were known. However, sensi-
tivity analyses did not alter the statistical significance for
each outcome, thereby demonstrating the robustness of
the findings. Third, the NASH Clinical Research Network
(NASH CRN) recently created a comprehensive scoring
system for clinical trials, the NAFLD Activity Score
(NAS);44 however, not all trials reported this score and
therefore we were not able to use the NAS as an endpoint
in our analysis. Finally, as with all studies that utilize histo-
logical endpoints, our findings are limited by the inherent
sampling variability with resultant inaccuracies sometimes
associated with liver biopsies. We feel that the notable
strengths of this meta-analysis, including the strict inclu-
sion criteria (RCTs with a histological definition of
NAFLD ⁄ NASH) and the assessment of both histological
and biochemical outcomes, outweigh its limitations.
In summary, it is evident from our findings that
whereas metformin is not an effective treatment for
NASH, the use of glitazones, on the other hand, results
in a significant biochemical improvement as well as
decrease in important histological components of NASH
such as steatosis and hepatocyte ballooning, but not
lobular inflammation or fibrosis. In patients without dia-
betes, glitazones produce a significant improvement in all
biochemical and histological outcomes, most significantly
including fibrosis. Despite this novel finding, there is
insufficient evidence at this time to make a strong rec-
ommendation for the use of glitazones in patients with-
out diabetes. Future studies are needed to investigate the
outcomes and potential benefits and toxicities of long-
term glitazone treatment in this subgroup of patients
with NASH. Moreover, additional studies in nondiabetics
are also needed to determine if glitazones offer incre-
mental benefit over anti-oxidants such as vitamin E,
which may be equally efficacious or more efficacious,25
without detrimental side effects such as weight gain.
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